|
1.Yanzhao Bi, Yifan Zhang, Chunying Cui*, Lulu Ren, Xueyun Jiang. Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7. Int J Nanomedicine. 2016,11:5771-5787.
2.Wen Zhao, Yifan Zhang, Xueyun Jiang, Chunying Cui*. Design, synthesis and evaluation of VEG F-siRNA /CRS as a novel vector for gene delivery. Drug Design, Development and Therapy. 2016,10:3851-3865
3.Chunying Cui, Yaonan Wang, Wen Zhao, Kaikai Yang, Xueyun Jiang, Shan Li, Ming Zhao, Yuanbo Song and Shiqi Peng*. RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay. J. Mater. Chem. B, 2015,3：9260-9268
4.Chunying Cui, Yuji Wang, Kaikai Yang, Yaonan Wang, Junyu Yang, Jianzhong Xi, Ming Zhao*, Jianhui Wu, and Shiqi Peng*. Preparation and Characterization of RGDS/Nanodiamond as a Vector for VEGF-siRNA Delivery. J. Biomed. Nanotechnol. 2015,11: 70-80
5.Cui Chunying, Wang Y, Wang Y, Zhao M*, Peng S*. Exploring the Relationship between the Inhibition Selectivity and the Apoptosis of Roscovitine-Treated Cancer Cells. J Anal Methods Chem. 2013;2013:389390. doi: 10.1155/2013/389390. Epub 2013 Apr 4.
6.Cui Chunying, Wang Y, Wang Y, Zhao M*, Peng S*. Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect. Journal of Analytical Methods in Chemistry Volume (2013), ttp://dx.doi.org/10.1155/2013/602091
7.Wang F#, Cui Chunying#, Ren Z, Wang L, Liu H, Cui G*. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif. J Pharm Sci. 2012 Dec;101(12):4559-68.
8.Du H#, Cui Chunying#, Wang L, Liu H, Cui G*. Novel Tetrapeptide, RGDF, Mediated Tumor Specific Liposomal Doxorubicin (DOX) Preparations.Mol Pharm. 2011 Aug 1;8(4):1224-32.
9.Chunying Cui, Yunwei Zhang, Lili Wang, Hu Liu and Guohui Cui*. Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid. Journal of Pharmacy and Pharmacology 2009; 61: 1353–1358.
10.Song N, Zhao M, Wang Y, Hu X, Wu J, Jiang X, Li S, Cui C, Peng S*. Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of S180 mice treated with MTX/MIT. Drug Des Devel Ther. 2016 Aug 30;10:2701-11.
11.Lv X, Zhao M, Wang Y, Hu X, Wu J, Jiang X, Li S, Cui C, Peng S*. Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy. Drug Design, Development and Therapy.2016,10:3933-3946
12.Meng Q, Yu X, Li C, Zhang C, Cui C, Luo D*. Possible mechanisms underlying the biphasic regulatory effects of arachidonic acid on Ca2+ signaling in HEK293 cells.Chen L, Cell Signal. 2012 Aug;24(8):1565-72. Epub 2012 Mar 30.
13.Liu Boyang, Chunying, Cui, guohuiCui*. Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta- arabinofuranosylcytosine. Eur J Med Chem 2009, Sep, 01;44(9):3596-600
14.Wen-Son Hsieh, Ross Soo, Bee-Keow Peh, Thomas Loh, Difeng Dong, Donny Soh, Lim-Soon Wong, Simon Green, Judy Chiao, Chunying Cui, Yoke-Fong Lai, Soo-Chin Lee, Benjamin Mow, Richie Soong, Manuel Salto-Tellez and Boon-Cher Goh*. Pharmacodynamic Effects of Seliciclib (R-Roscovitine, CYC202) in Patients with Undifferentiated Nasopharyngeal Cancer (NPC) Using a Window Trial Design. Cancer research. Clinical Cancer Research. 2009 February 15, 15：1435
15.Chun-Ying Cui, Wan-Liang Lu, Lan Xiao, Qiang Zhang*. Sublingual Delivery of Insulin: Effects of Enhancers on the Mucosal Lipid Fluidity and Protein Conformation, the Transport, and the In Vivo Hypoglycemic Activity. Biological & Pharmaceutical Bulletin, Vol 28 (12)：2279-2288, 2005.
|
